The Food and Drug Administration says it has approved a long-delayed
inhalable diabetes medication to help patients control their blood sugar
levels.
The FDA cleared MannKind Corp.'s drug Afrezza, a fast-acting form of
insulin, for adults with the most common form of diabetes, which affects
more than 25 million Americans. The approval decision comes more than
three years after the agency first asked MannKind to run additional
clinical studies on the drug.
Afrezza, an insulin powder, comes in a single-use cartridge and is
designed to be inhaled at the start of a meal. MannKind has said
patients using the drug can achieve peak insulin levels within 12 to 15
minutes. That compares to a wait time of an hour and a half or more
after patients inject insulin.
No comments:
Post a Comment